Insight velocity
Turn days of work into hours with reliable AI-driven analysis.


















































Purpose-built for teams who need real insights—so you can focus on decisions, not research.

Purpose-built for teams who need real insights—so you can focus on decisions, not research.
Strategic decisions deserve more than gut checks and stale decks. Maven Bio gives your team evidence-backed insights—and a living view of the market that doesn't go stale the moment it's built.







Speed is table stakes. Maven Bio gives your team the primary-source depth to deliver work that wins engagements—and keeps them.





IC questions deserve real answers. Maven Bio surfaces primary source analysis so your team builds theses that hold up under pressure.







Turn days of work into hours with reliable AI-driven analysis.
Execute large-scale screens once too slow or impractical to run.
Operationalize your frameworks so they're applied consistently by everyone.
Every insight tied directly to primary sources and reasoning for defensible decisions.

Powered by the most expansive collection of curated life sciences data.

Powered by the most expansive collection of curated life sciences data.






An analysis of how major pharmaceutical companies rebalanced revenue across therapeutic areas between 2019 and 2024, highlighting oncology concentration, portfolio diversification, and the commercial impact of M&A and new blockbusters.

An analysis of the current clinical-stage landscape for KRAS-targeted therapies, examining the divergence between KRAS G12D–selective programs and pan-KRAS approaches, development maturity, and emerging tumor-specific strategies in pancreatic cancer.

A research report analyzing the launch velocity of new molecular entities (NMEs) and biologic entities (NBEs) across major pharmaceutical companies from 2021 to 2025.